메뉴 건너뛰기




Volumn 8, Issue 10, 2012, Pages 1337-1356

An evaluation of sirolimus in renal transplantation

Author keywords

Calcineurin inhibitors; Kidney transplantation; MTOR inhibitors; Rapamycin; Sirolimus

Indexed keywords

AZATHIOPRINE; BELATACEPT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; RIDAFOROLIMUS; SOTRASTAURIN; STEROID; TACROLIMUS; TEMSIROLIMUS; TOFACITINIB;

EID: 84866524136     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.719874     Document Type: Article
Times cited : (26)

References (217)
  • 1
    • 77954543448 scopus 로고    scopus 로고
    • The 2007 ERA-EDTA registry annual report-a precis
    • Stel VS, Kramer A, Zoccali C, Jager KJ. The 2007 ERA-EDTA registry annual report-a precis. NDT Plus 2009;2:514-21
    • (2009) NDT Plus , vol.2 , pp. 514-521
    • Stel, V.S.1    Kramer, A.2    Zoccali, C.3    Jager, K.J.4
  • 2
    • 84866506169 scopus 로고    scopus 로고
    • National institute of diabetes and digestive and kidney diseases
    • US Renal Data System UADTAoCKDaE-SRDitUS NIoH MD
    • US Renal Data System UADTAoCKDaE-SRDitUS NIoH. National institute of diabetes and digestive and kidney diseases. Bethesda, MD: 2009
    • (2009) Bethesda
  • 3
    • 10844266734 scopus 로고    scopus 로고
    • Transplantation 50 years later - Progress, challenges, and promises
    • DOI 10.1056/NEJMon043418
    • Sayegh MH, Carpenter CB. Transplantation 50 years later-progress, challenges, and promises. N Engl J Med 2004;351:2761-6 (Pubitemid 39665333)
    • (2004) New England Journal of Medicine , vol.351 , Issue.26 , pp. 2761-2766
    • Sayegh, M.H.1    Carpenter, C.B.2
  • 5
    • 33749834063 scopus 로고    scopus 로고
    • Sirolimus-challenging current perspectives
    • Buhaescu I, Izzedine H, Covic A. Sirolimus-challenging current perspectives. Ther Drug Monit 2006;28:577-84
    • (2006) Ther Drug Monit , vol.28 , pp. 577-584
    • Buhaescu, I.1    Izzedine, H.2    Covic, A.3
  • 6
    • 23244451207 scopus 로고    scopus 로고
    • Gastrointestinal complications in renal transplant recipients
    • DOI 10.1111/j.1432-2277.2005.00134.x
    • Ponticelli C, Passerini P. Gastrointestinal complications in renal transplant recipients. Transpl Int 2005;18:643-50 (Pubitemid 41726826)
    • (2005) Transplant International , vol.18 , Issue.6 , pp. 643-650
    • Ponticelli, C.1    Passerini, P.2
  • 7
    • 73649124549 scopus 로고    scopus 로고
    • Chronic calcineurin inhibitor nephrotoxicity: Reflections on an evolving paradigm
    • Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: Reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009;4:2029-34
    • (2009) Clin J Am Soc Nephrol , vol.4 , pp. 2029-2034
    • Gaston, R.S.1
  • 9
    • 77957196426 scopus 로고    scopus 로고
    • An integrated view of molecular changes, histopathology and outcomes in kidney transplants
    • Halloran PF, de Freitas DG, Einecke G, et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010;10:2223-30
    • (2010) Am J Transplant , vol.10 , pp. 2223-2230
    • Halloran, P.F.1    De Freitas, D.G.2    Einecke, G.3
  • 10
    • 48749127228 scopus 로고    scopus 로고
    • Chronic allograft nephropathy-clinical guidance for early detection and early intervention strategies
    • Seron D, Arns W, Chapman Jr. Chronic allograft nephropathy-clinical guidance for early detection and early intervention strategies. Nephrol Dial Transplant 2008;23:2467-73
    • (2008) Nephrol Dial Transplant , vol.23 , pp. 2467-2473
    • Seron, D.1    Arns, W.2    Chapman, J.R.3
  • 11
    • 80054712257 scopus 로고    scopus 로고
    • Diagnosis and prevention of chronic kidney allograft loss
    • Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011;378:1428-37
    • (2011) Lancet , Issue.378 , pp. 1428-1437
    • Nankivell, B.J.1    Kuypers, D.R.2
  • 12
    • 70350500090 scopus 로고    scopus 로고
    • Immunosuppressive drugs in kidney transplantation: Impact on patient survival, and incidence of cardiovascular disease, malignancy and infection
    • Marcen R. Immunosuppressive drugs in kidney transplantation: Impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009;69:2227-43
    • (2009) Drugs , vol.69 , pp. 2227-2243
    • Marcen, R.1
  • 13
    • 0036820323 scopus 로고    scopus 로고
    • Cardiovascular toxicities of immunosuppressive agents
    • DOI 10.1034/j.1600-6143.2002.20902.x
    • Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2:807-18 (Pubitemid 36306835)
    • (2002) American Journal of Transplantation , vol.2 , Issue.9 , pp. 807-818
    • Miller, L.W.1
  • 14
    • 77951702257 scopus 로고    scopus 로고
    • Chronic kidney disease and cancer: A troubling connection
    • Stengel B. Chronic kidney disease and cancer: A troubling connection. J Nephrol 2010;23:253-62
    • (2010) J Nephrol , Issue.23 , pp. 253-262
    • Stengel, B.1
  • 15
    • 74949094555 scopus 로고    scopus 로고
    • KDIGO clinical practice guideline for the care of kidney transplant recipients
    • KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155
    • (2009) Am J Transplant , vol.9 , Issue.SUPPL. 3
  • 16
    • 80053560264 scopus 로고    scopus 로고
    • Immunosuppression after kidney transplantation
    • European Association of Urology (EAU Arnhem, The Netherlands
    • Kälble T, Alcaraz A, Budde K, et al. Immunosuppression after kidney transplantation. In: Guidelines on renal transplantation. European Association of Urology (EAU); Arnhem, The Netherlands: 2010
    • (2010) Guidelines on Renal Transplantation
    • Kälble, T.1    Alcaraz, A.2    Budde, K.3
  • 17
    • 70349175792 scopus 로고    scopus 로고
    • The role of antibodies in transplantation
    • Chang AT, Platt JL. The role of antibodies in transplantation. Transplant Rev (Orlando) 2009;23:191-8
    • (2009) Transplant Rev (Orlando , vol.23 , pp. 191-198
    • Chang, A.T.1    Platt, J.L.2
  • 18
    • 33745013619 scopus 로고    scopus 로고
    • Target of rapamycin inhibitors TOR -I; Sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
    • Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006(2):CD004290
    • (2006) Cochrane Database Syst Rev , Issue.2
    • Webster, A.C.1    Lee, V.W.2    Chapman, J.R.3    Craig, J.C.4
  • 19
    • 36248931517 scopus 로고    scopus 로고
    • Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors
    • DOI 10.1016/j.trre.2007.09.003, PII S0955470X07000948
    • Cruzado JM. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transplant Rev (Orlando) 2008;22:73-81 (Pubitemid 350131581)
    • (2008) Transplantation Reviews , vol.22 , Issue.1 , pp. 73-81
    • Cruzado, J.M.1
  • 20
    • 33645458234 scopus 로고    scopus 로고
    • Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation
    • Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581-9
    • (2006) J Am Soc Nephrol , vol.17 , pp. 581-589
    • Campistol, J.M.1    Eris, J.2    Oberbauer, R.3
  • 21
    • 58149132428 scopus 로고    scopus 로고
    • Cyclosporin and organ specific toxicity: Clinical aspects, pharmacogenetics and perspectives
    • Magnasco A, Rossi A, Catarsi P, et al. Cyclosporin and organ specific toxicity: Clinical aspects, pharmacogenetics and perspectives. Curr Clin Pharmacol 2008;3:166-73
    • (2008) Curr Clin Pharmacol , vol.3 , pp. 166-173
    • Magnasco, A.1    Rossi, A.2    Catarsi, P.3
  • 23
    • 33644876434 scopus 로고    scopus 로고
    • Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients
    • Webster A, Woodroffe RC, Taylor RS, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005(4):CD003961
    • (2005) Cochrane Database Syst Rev , Issue.4
    • Webster, A.1    Woodroffe, R.C.2    Taylor, R.S.3
  • 24
    • 67649586577 scopus 로고    scopus 로고
    • Cyclosporine withdrawal improves long-term graft survival in renal transplantation
    • Gallagher M, Jardine M, Perkovic V, et al. Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation 2009;87:1877-83
    • (2009) Transplantation , vol.87 , pp. 1877-1883
    • Gallagher, M.1    Jardine, M.2    Perkovic, V.3
  • 28
    • 0033774719 scopus 로고    scopus 로고
    • A meta-analysis of immunosuppression withdrawal trials in renal transplantation
    • Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000;11:1910-17
    • (2000) J Am Soc Nephrol , vol.11 , pp. 1910-1917
    • Kasiske, B.L.1    Chakkera, H.A.2    Louis, T.A.3    Ma, J.Z.4
  • 29
    • 20344363422 scopus 로고    scopus 로고
    • The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation
    • DOI 10.1016/j.transproceed.2005.03.072, PII S0041134505003106
    • Satoh S, Tada H, Murakami M, et al. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation. Transplant Proc 2005;37:1751-3 (Pubitemid 40790819)
    • (2005) Transplantation Proceedings , vol.37 , Issue.4 , pp. 1751-1753
    • Satoh, S.1    Tada, H.2    Murakami, M.3    Tsuchiya, N.4    Inoue, T.5    Togashi, H.6    Matsuura, S.7    Hayase, Y.8    Suzuki, T.9    Habuchi, T.10
  • 31
    • 0031024728 scopus 로고    scopus 로고
    • Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection
    • DOI 10.1097/00007890-199701150-00008
    • Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63:39-47 (Pubitemid 27036687)
    • (1997) Transplantation , vol.63 , Issue.1 , pp. 39-47
    • Halloran, P.1    Mathew, T.2    Tomlanovich, S.3    Groth, C.4    Hooftman, L.5    Barker, C.6
  • 32
    • 65549141734 scopus 로고    scopus 로고
    • Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation
    • Opelz G, Dohler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009;87:795-802
    • (2009) Transplantation , vol.87 , pp. 795-802
    • Opelz, G.1    Dohler, B.2
  • 33
    • 80555134743 scopus 로고    scopus 로고
    • Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation
    • Sharif A, Shabir S, Chand S, et al. Meta-analysis of calcineurin- inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011;22:2107-18
    • (2011) J Am Soc Nephrol , vol.22 , pp. 2107-2118
    • Sharif, A.1    Shabir, S.2    Chand, S.3
  • 36
    • 1942502227 scopus 로고    scopus 로고
    • Withdrawal of Cyclosporine or Tacrolimus after Addition of Mycophenolate Mofetil in Patients with Chronic Allograft Nephropathy
    • DOI 10.1111/j.1600-6143.2004.00404.x
    • Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004;4:655-62 (Pubitemid 38523590)
    • (2004) American Journal of Transplantation , vol.4 , Issue.4 , pp. 655-662
    • Suwelack, B.1    Gerhardt, U.2    Hohage, H.3
  • 37
    • 14044252180 scopus 로고    scopus 로고
    • Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: The 'creeping creatinine' study
    • DOI 10.1097/01.TP.0000151632.21551.00
    • Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study. Transplantation 2005;79:466-75 (Pubitemid 40280180)
    • (2005) Transplantation , vol.79 , Issue.4 , pp. 466-475
    • Dudley, C.1    Pohanka, E.2    Riad, H.3    Dedochova, J.4    Wijngaard, P.5    Sutter, C.6    Silva Jr., H.T.7
  • 38
    • 70350131319 scopus 로고    scopus 로고
    • Mycophenolate mofetil and calcineurin-inhibitor reduction: Recent progress
    • Grinyo JM, Cruzado JM. Mycophenolate mofetil and calcineurin-inhibitor reduction: Recent progress. Am J Transplant 2009;9:2447-52
    • (2009) Am J Transplant , vol.9 , pp. 2447-2452
    • Grinyo, J.M.1    Cruzado, J.M.2
  • 42
    • 79961028817 scopus 로고    scopus 로고
    • Long-Term impact of cyclosporin reduction with MMF treatment in chronic allograft dysfunction: Referenece study 3-year follow up
    • 2010pii
    • Frimat L, Cassuto-Viguier E, Provot F, et al. Long-Term impact of cyclosporin reduction with MMF treatment in chronic allograft dysfunction: Referenece study 3-year follow up. J Transplant 2010;2010:pii: 402750
    • (2010) J Transplant , pp. 402750
    • Frimat, L.1    Cassuto-Viguier, E.2    Provot, F.3
  • 43
    • 65649141573 scopus 로고    scopus 로고
    • Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta-analysis
    • Moore J, Middleton L, Cockwell P, et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta-analysis. Transplantation 2009;87:591-605
    • (2009) Transplantation , vol.87 , pp. 591-605
    • Moore, J.1    Middleton, L.2    Cockwell, P.3
  • 44
    • 77954347112 scopus 로고    scopus 로고
    • Effects of the new immunosuppressive agent AEB071 on human immune cells
    • Matz M, Weber U, Mashreghi MF, et al. Effects of the new immunosuppressive agent AEB071 on human immune cells. Nephrol Dial Transplant 2010;25:2159-67
    • (2010) Nephrol Dial Transplant , vol.25 , pp. 2159-2167
    • Matz, M.1    Weber, U.2    Mashreghi, M.F.3
  • 45
    • 77955478891 scopus 로고    scopus 로고
    • AEB-071 versus tacrolimus monotherapy to prevent acute cardiac allograft rejection in the rat: A preliminary report
    • Fang YH, Joo DJ, Lim BJ, et al. AEB-071 versus tacrolimus monotherapy to prevent acute cardiac allograft rejection in the rat: A preliminary report. Transplant Proc 2010;42:976-9
    • (2010) Transplant Proc , vol.42 , pp. 976-979
    • Fang, Y.H.1    Joo, D.J.2    Lim, B.J.3
  • 46
    • 70350439236 scopus 로고    scopus 로고
    • Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients
    • Quaedackers ME, Mol W, Korevaar SS, et al. Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation 2009;88:1002-9
    • (2009) Transplantation , vol.88 , pp. 1002-1009
    • Quaedackers, M.E.1    Mol, W.2    Korevaar, S.S.3
  • 47
    • 67650938638 scopus 로고    scopus 로고
    • Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: A pilot study in de novo kidney allograft recipients
    • Busque S, Leventhal J, Brennan DC, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: A pilot study in de novo kidney allograft recipients. Am J Transplant 2009;9:1936-45
    • (2009) Am J Transplant , vol.9 , pp. 1936-1945
    • Busque, S.1    Leventhal, J.2    Brennan, D.C.3
  • 48
    • 77956528156 scopus 로고    scopus 로고
    • Five-year safety and efficacy of belatacept in renal transplantation
    • Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010;21:1587-96
    • (2010) J Am Soc Nephrol , vol.21 , pp. 1587-1596
    • Vincenti, F.1    Blancho, G.2    Durrbach, A.3
  • 49
    • 76949090842 scopus 로고    scopus 로고
    • A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)
    • Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010;10:547-57
    • (2010) Am J Transplant , Issue.10 , pp. 547-557
    • Durrbach, A.1    Pestana, J.M.2    Pearson, T.3
  • 50
    • 76949101581 scopus 로고    scopus 로고
    • A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)
    • Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010;10:535-46
    • (2010) Am J Transplant , Issue.10 , pp. 535-546
    • Vincenti, F.1    Charpentier, B.2    Vanrenterghem, Y.3
  • 51
    • 78650887509 scopus 로고    scopus 로고
    • Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients
    • Ferguson R, Grinyo J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011;11:66-76
    • (2011) Am J Transplant , vol.11 , pp. 66-76
    • Ferguson, R.1    Grinyo, J.2    Vincenti, F.3
  • 53
    • 84858444345 scopus 로고    scopus 로고
    • Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: Observational results at 24 and 36months after transplantation
    • Guba M, Pratschke J, Hugo C, et al. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: Observational results at 24 and 36months after transplantation. Transpl Int 2012;25:416-23
    • (2012) Transpl Int , vol.25 , pp. 416-423
    • Guba, M.1    Pratschke, J.2    Hugo, C.3
  • 54
    • 84857194014 scopus 로고    scopus 로고
    • Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials
    • Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials. Am J Transplant 2011;11:2453-62
    • (2011) Am J Transplant , vol.11 , pp. 2453-2462
    • Brennan, D.C.1    Legendre, C.2    Patel, D.3
  • 56
    • 34447629364 scopus 로고    scopus 로고
    • BK virus-associated nephropathy in sirolimus-treated renal transplant patients: Incidence, course, and clinical outcomes
    • DOI 10.1097/01.tp.0000268524.27506.39, PII 0000789020070715000016
    • Benavides CA, Pollard VB, Mauiyyedi S, et al. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: Incidence, course, and clinical outcomes. Transplantation 2007;84:83-8 (Pubitemid 47094646)
    • (2007) Transplantation , vol.84 , Issue.1 , pp. 83-88
    • Benavides, C.A.1    Pollard, V.B.2    Mauiyyedi, S.3    Podder, H.4    Knight, R.5    Kahan, B.D.6
  • 57
    • 77749237077 scopus 로고    scopus 로고
    • MTOR inhibitor/proliferation signal inhibitors: Entering or leaving the field?
    • Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitors: Entering or leaving the field? J Nephrol 2010;23:133-42
    • (2010) J Nephrol , vol.23 , pp. 133-142
    • Rostaing, L.1    Kamar, N.2
  • 58
    • 84863103806 scopus 로고    scopus 로고
    • The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen
    • Suwelack B, Malyar V, Koch M, et al. The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant Rev (Orlando) 2012;26:201-11
    • (2012) Transplant Rev (Orlando , vol.26 , pp. 201-211
    • Suwelack, B.1    Malyar, V.2    Koch, M.3
  • 59
    • 84862290097 scopus 로고    scopus 로고
    • Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients
    • Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012;93:1075-85
    • (2012) Transplantation , vol.93 , pp. 1075-1085
    • Nashan, B.1    Gaston, R.2    Emery, V.3
  • 60
    • 0025902276 scopus 로고
    • Preclinical evaluation of a new potent immunosuppressive agent, rapamycin
    • Kahan BD, Chang JY, Sehgal SN. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991;52:185-91
    • (1991) Transplantation , vol.52 , pp. 185-191
    • Kahan, B.D.1    Chang, J.Y.2    Sehgal, S.N.3
  • 61
    • 0016713286 scopus 로고
    • Rapamycin (AY-22,989), a new antifungal antibiotic II Fermentation, isolation and characterization
    • Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28:727-32
    • (1975) J Antibiot (Tokyo , vol.28 , pp. 727-732
    • Sehgal, S.N.1    Baker, H.2    Vezina, C.3
  • 62
    • 32044465506 scopus 로고    scopus 로고
    • TOR signaling in growth and metabolism
    • DOI 10.1016/j.cell.2006.01.016, PII S0092867406001085
    • Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84 (Pubitemid 43199434)
    • (2006) Cell , vol.124 , Issue.3 , pp. 471-484
    • Wullschleger, S.1    Loewith, R.2    Hall, M.N.3
  • 63
    • 84858637583 scopus 로고    scopus 로고
    • Everolimus: Preventing organ rejection in adult kidney transplant recipients
    • Dantal J. Everolimus: Preventing organ rejection in adult kidney transplant recipients. Expert Opin Pharmacother 2012;13:767-78
    • (2012) Expert Opin Pharmacother , vol.13 , pp. 767-778
    • Dantal, J.1
  • 65
    • 0025776523 scopus 로고
    • Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast
    • Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991;253:905-9 (Pubitemid 21917235)
    • (1991) Science , vol.253 , Issue.5022 , pp. 905-909
    • Hietman, J.1    Movva, N.R.2    Hall, M.N.3
  • 66
    • 4043171462 scopus 로고    scopus 로고
    • Upstream and downstream of mTOR
    • DOI 10.1101/gad.1212704
    • Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45 (Pubitemid 39071573)
    • (2004) Genes and Development , vol.18 , Issue.16 , pp. 1926-1945
    • Hay, N.1    Sonenberg, N.2
  • 67
    • 0043127125 scopus 로고    scopus 로고
    • Rheb GTpase is a direct target of TSC2 GAP activity and regulates mTOR signaling
    • DOI 10.1101/gad.1110003
    • Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-34 (Pubitemid 36944560)
    • (2003) Genes and Development , vol.17 , Issue.15 , pp. 1829-1834
    • Inoki, K.1    Li, Y.2    Xu, T.3    Guan, K.-L.4
  • 68
    • 67649344456 scopus 로고    scopus 로고
    • Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR
    • Wang L, Lawrence JC Jr, Sturgill TW, Harris TE. Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR. J Biol Chem 2009;284:14693-7
    • (2009) J Biol Chem , vol.284 , pp. 14693-14697
    • Wang, L.1    Lawrence Jr., J.C.2    Sturgill, T.W.3    Harris, T.E.4
  • 69
    • 34548700597 scopus 로고    scopus 로고
    • Rapamycin: Something old, something new, sometimes borrowed and now renewed
    • DOI 10.1038/sj.clpt.6100317, PII 6100317
    • Hartford CM, Ratain MJ. Rapamycin: Something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007;82:381-8 (Pubitemid 47414349)
    • (2007) Clinical Pharmacology and Therapeutics , vol.82 , Issue.4 , pp. 381-388
    • Hartford, C.M.1    Ratain, M.J.2
  • 70
    • 33746637660 scopus 로고    scopus 로고
    • Current development of mTOR inhibitors as anticancer agents
    • DOI 10.1038/nrd2062, PII NRD2062
    • Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88 (Pubitemid 44151605)
    • (2006) Nature Reviews Drug Discovery , vol.5 , Issue.8 , pp. 671-688
    • Faivre, S.1    Kroemer, G.2    Raymond, E.3
  • 71
    • 0028869086 scopus 로고
    • Rapamune (Sirolimus, rapamycin): An overview and mechanism of action
    • Sehgal SN. Rapamune (Sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit 1995;17:660-5
    • (1995) Ther Drug Monit , vol.17 , pp. 660-665
    • Sehgal, S.N.1
  • 74
    • 33646023695 scopus 로고    scopus 로고
    • Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
    • Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68
    • (2006) Mol Cell , vol.22 , pp. 159-168
    • Sarbassov, D.D.1    Ali, S.M.2    Sengupta, S.3
  • 75
    • 10844292763 scopus 로고    scopus 로고
    • Immunosuppressive drugs for kidney transplantation
    • DOI 10.1056/NEJMra033540
    • Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29 (Pubitemid 39665325)
    • (2004) New England Journal of Medicine , vol.351 , Issue.26 , pp. 2715-2729
    • Halloran, P.F.1
  • 76
    • 52549127241 scopus 로고    scopus 로고
    • Toll-like receptor-mediated induction of type i interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTORp70S6K pathway
    • Cao W, Manicassamy S, Tang H, et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTORp70S6K pathway. Nat Immunol 2008;9:1157-64
    • (2008) Nat Immunol , vol.9 , pp. 1157-1164
    • Cao, W.1    Manicassamy, S.2    Tang, H.3
  • 79
    • 67650074206 scopus 로고    scopus 로고
    • MTOR regulates memory CD8 T-cell differentiation
    • Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108-12
    • (2009) Nature , vol.460 , pp. 108-112
    • Araki, K.1    Turner, A.P.2    Shaffer, V.O.3
  • 80
    • 78349313076 scopus 로고    scopus 로고
    • The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation
    • Geissler EK, Schlitt HJ. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int 2010;78:1075-9
    • (2010) Kidney Int , vol.78 , pp. 1075-1079
    • Geissler, E.K.1    Schlitt, H.J.2
  • 81
    • 58149143166 scopus 로고    scopus 로고
    • Effects of immunosuppressive drugs on purified human B cells: Evidence supporting the use of MMF and rapamycin
    • Heidt S, Roelen DL, Eijsink C, et al. Effects of immunosuppressive drugs on purified human B cells: Evidence supporting the use of MMF and rapamycin. Transplantation 2008;86:1292-300
    • (2008) Transplantation , vol.86 , pp. 1292-1300
    • Heidt, S.1    Roelen, D.L.2    Eijsink, C.3
  • 82
    • 78649848404 scopus 로고    scopus 로고
    • Sirolimus and kidney transplantation: Unraveling an inflammatory affair
    • Weichhart T, Saemann MD. Sirolimus and kidney transplantation: Unraveling an inflammatory affair. Am J Transplant 2010;10:2569-70
    • (2010) Am J Transplant , Issue.10 , pp. 2569-2570
    • Weichhart, T.1    Saemann, M.D.2
  • 83
    • 72449147738 scopus 로고    scopus 로고
    • The multifunctional role of mTOR in innate immunity: Implications for transplant immunity
    • Saemann MD, Haidinger M, Hecking M, et al. The multifunctional role of mTOR in innate immunity: Implications for transplant immunity. Am J Transplant 2009;9:2655-61
    • (2009) Am J Transplant , vol.9 , pp. 2655-2661
    • Saemann, M.D.1    Haidinger, M.2    Hecking, M.3
  • 84
    • 44549083892 scopus 로고    scopus 로고
    • Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients
    • Bohler T, Waiser J, Lichter S, et al. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients. Cytokine 2008;42:306-11
    • (2008) Cytokine , vol.42 , pp. 306-311
    • Bohler, T.1    Waiser, J.2    Lichter, S.3
  • 85
    • 33745307617 scopus 로고    scopus 로고
    • Ras, PI(3)K and mTOR signalling controls tumour cell growth
    • DOI 10.1038/nature04869, PII NATURE04869
    • Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30 (Pubitemid 44050136)
    • (2006) Nature , vol.441 , Issue.7092 , pp. 424-430
    • Shaw, R.J.1    Cantley, L.C.2
  • 86
    • 38049169559 scopus 로고    scopus 로고
    • Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis
    • Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-51
    • (2008) N Engl J Med , vol.358 , pp. 140-151
    • Bissler, J.J.1    McCormack, F.X.2    Young, L.R.3
  • 87
    • 77957659746 scopus 로고    scopus 로고
    • Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology
    • Gabardi S, Baroletti SA. Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010;30:1044-56
    • (2010) Pharmacotherapy , vol.30 , pp. 1044-1056
    • Gabardi, S.1    Baroletti, S.A.2
  • 90
    • 84860633618 scopus 로고    scopus 로고
    • Dose-Dependent effects of sirolimus on mTOR signaling and polycystic kidney disease
    • Novalic Z, van der Wal AM, Leonhard WN, et al. Dose-Dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 2012;23:842-53
    • (2012) J Am Soc Nephrol , Issue.23 , pp. 842-853
    • Novalic, Z.1    Van Der Wal, A.M.2    Leonhard, W.N.3
  • 91
    • 79951674629 scopus 로고    scopus 로고
    • Mtor and rapamycin in the kidney: Signaling and therapeutic implications beyond immunosuppression
    • Huber TB, Walz G, Kuehn EW. mTOR and rapamycin in the kidney: Signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011;79:502-11
    • (2011) Kidney Int , Issue.79 , pp. 502-511
    • Huber, T.B.1    Walz, G.2    Kuehn, E.W.3
  • 92
    • 32844467779 scopus 로고    scopus 로고
    • Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: A novel approach for tailored immunosuppressive therapy
    • DOI 10.1111/j.1523-1755.2005.00731.x, PII 4495604
    • Hartmann B, Schmid G, Graeb C, et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: A novel approach for tailored immunosuppressive therapy. Kidney Int 2005;68:2593-8 (Pubitemid 43251005)
    • (2005) Kidney International , vol.68 , Issue.6 , pp. 2593-2598
    • Hartmann, B.1    Schmid, G.2    Graeb, C.3    Bruns, C.J.4    Fischereder, M.5    Jauch, K.-W.6    Heeschen, C.7    Guba, M.8
  • 93
    • 58749102772 scopus 로고    scopus 로고
    • Pharmacokinetic principles of immunosuppressive drugs
    • Budde K, Glander P. Pharmacokinetic principles of immunosuppressive drugs. Ann Transplant 2008;13:5-10
    • (2008) Ann Transplant , vol.13 , pp. 5-10
    • Budde, K.1    Glander, P.2
  • 95
    • 33847314632 scopus 로고    scopus 로고
    • Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma
    • Di Paolo S, Teutonico A, Ranieri E, et al. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. Am J Kidney Dis 2007;49:462-70
    • (2007) Am J Kidney Dis , vol.49 , pp. 462-470
    • Di Paolo, S.1    Teutonico, A.2    Ranieri, E.3
  • 96
    • 0033376927 scopus 로고    scopus 로고
    • Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients
    • DOI 10.1002/(SICI)1099-081X(199907)20:5<249::AID-BDD181>3.0.CO;2-9
    • Kelly PA, Napoli K, Kahan BD. Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. Biopharm Drug Dispos 1999;20:249-53 (Pubitemid 30021069)
    • (1999) Biopharmaceutics and Drug Disposition , vol.20 , Issue.5 , pp. 249-253
    • Kelly, P.A.1    Napoli, K.2    Kahan, B.D.3
  • 97
    • 0034804744 scopus 로고    scopus 로고
    • From beach to bedside: History of the development of sirolimus
    • DOI 10.1097/00007691-200110000-00012
    • Napoli KL, Taylor PJ. From beach to bedside: History of the development of sirolimus. Ther Drug Monit 2001;23:559-86 (Pubitemid 32912281)
    • (2001) Therapeutic Drug Monitoring , vol.23 , Issue.5 , pp. 559-586
    • Napoli, K.L.1    Taylor, P.J.2
  • 98
    • 0034870203 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of sirolimus
    • Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001;40:573-85 (Pubitemid 32758580)
    • (2001) Clinical Pharmacokinetics , vol.40 , Issue.8 , pp. 573-585
    • Mahalati, K.1    Kahan, B.D.2
  • 99
    • 0033346578 scopus 로고    scopus 로고
    • The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin)
    • Zimmerman JJ, Ferron GM, Lim HK, Parker V. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol 1999;39:1155-61 (Pubitemid 30644018)
    • (1999) Journal of Clinical Pharmacology , vol.39 , Issue.11 , pp. 1155-1161
    • Zimmerman, J.J.1    Ferron, G.M.2    Lim, H.-K.3    Parker, V.4
  • 100
    • 13144256680 scopus 로고    scopus 로고
    • The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent
    • DOI 10.1016/S0009-9236(98)90120-5
    • Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998;63:48-53 (Pubitemid 28070185)
    • (1998) Clinical Pharmacology and Therapeutics , vol.63 , Issue.1 , pp. 48-53
    • Kaplan, B.1    Meier-Kriesche, H.-U.2    Napoli, K.L.3    Kahan, B.D.4
  • 104
    • 77949352391 scopus 로고    scopus 로고
    • Immunosuppressant neurotoxicity in rat brain models: Oxidative stress and cellular metabolism
    • Klawitter J, Gottschalk S, Hainz C, et al. Immunosuppressant neurotoxicity in rat brain models: Oxidative stress and cellular metabolism. Chem Res Toxicol 2010;23:608-19
    • (2010) Chem Res Toxicol , vol.23 , pp. 608-619
    • Klawitter, J.1    Gottschalk, S.2    Hainz, C.3
  • 105
    • 78951486001 scopus 로고    scopus 로고
    • Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism
    • Gottschalk S, Cummins CL, Leibfritz D, et al. Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. Neurotoxicology 2011;32:50-7
    • (2011) Neurotoxicology , Issue.32 , pp. 50-57
    • Gottschalk, S.1    Cummins, C.L.2    Leibfritz, D.3
  • 106
    • 76149139441 scopus 로고    scopus 로고
    • Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: A proteo-metabonomic study
    • Klawitter J, Kushner E, Jonscher K, et al. Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: A proteo-metabonomic study. J Proteome Res 2010;9:865-75
    • (2010) J Proteome Res , vol.9 , pp. 865-875
    • Klawitter, J.1    Kushner, E.2    Jonscher, K.3
  • 107
    • 67649087986 scopus 로고    scopus 로고
    • Metabolic profiles in urine reflect nephrotoxicity of sirolimus and cyclosporine following rat kidney transplantation
    • Schmitz V, Klawitter J, Bendrick-Peart J, et al. Metabolic profiles in urine reflect nephrotoxicity of sirolimus and cyclosporine following rat kidney transplantation. Nephron Exp Nephrol 2009;111:e80-91
    • (2009) Nephron Exp Nephrol , vol.111
    • Schmitz, V.1    Klawitter, J.2    Bendrick-Peart, J.3
  • 108
    • 61849137160 scopus 로고    scopus 로고
    • Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function
    • Klawitter J, Bendrick-Peart J, Rudolph B, et al. Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem Res Toxicol 2009;22:118-28
    • (2009) Chem Res Toxicol , vol.22 , pp. 118-128
    • Klawitter, J.1    Bendrick-Peart, J.2    Rudolph, B.3
  • 110
    • 0032128447 scopus 로고    scopus 로고
    • Rapamycin: Distribution, pharmacokinetics and therapeutic range investigations: An update
    • DOI 10.1016/S0009-9120(98)00048-4, PII S0009912098000484
    • Trepanier DJ, Gallant H, Legatt DF, Yatscoff RW. Rapamycin: Distribution, pharmacokinetics and therapeutic range investigations: An update. Clin Biochem 1998;31:345-51 (Pubitemid 28385233)
    • (1998) Clinical Biochemistry , vol.31 , Issue.5 , pp. 345-351
    • Trepanier, D.J.1    Gallant, H.2    Legatt, D.F.3    Yatscoff, R.W.4
  • 112
    • 0030064388 scopus 로고    scopus 로고
    • The side effect profile of sirolimus: A phase i study in quiescent cyclosporine-prednisone-treated renal transplant patients
    • Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996;49:209-16 (Pubitemid 26024236)
    • (1996) Kidney International , vol.49 , Issue.1 , pp. 209-216
    • Murgia, M.G.1    Jordan, S.2    Kahan, B.D.3
  • 113
    • 0033610638 scopus 로고    scopus 로고
    • Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial rapamune study group
    • Kahan BD, Julian BA, Pescovitz MD, et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group. Transplantation 1999;68:1526-32
    • (1999) Transplantation , vol.68 , pp. 1526-1532
    • Kahan, B.D.1    Julian, B.A.2    Pescovitz, M.D.3
  • 114
    • 33746530366 scopus 로고    scopus 로고
    • Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
    • Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356:194-202 (Pubitemid 30446974)
    • (2000) Lancet , vol.356 , Issue.9225 , pp. 194-202
    • Kahan, B.D.1
  • 115
    • 0035956745 scopus 로고    scopus 로고
    • A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
    • MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001;71:271-80 (Pubitemid 32126112)
    • (2001) Transplantation , vol.71 , Issue.2 , pp. 271-280
    • MacDonald, A.S.1
  • 116
    • 0038637990 scopus 로고    scopus 로고
    • Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation
    • DOI 10.1016/S0041-1345(03)00353-1
    • Kahan BD. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003;35:37S-51S (Pubitemid 36547914)
    • (2003) Transplantation Proceedings , vol.35 , Issue.SUPPL. 3
    • Kahan, B.D.1
  • 117
    • 0034728055 scopus 로고    scopus 로고
    • Sirolimus-tacrolimus combination immunosuppression
    • 117. McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000;355:376-7
    • (2000) Lancet , Issue.355 , pp. 376-377
    • McAlister, V.C.1    Gao, Z.2    Peltekian, K.3
  • 118
    • 0037469039 scopus 로고    scopus 로고
    • Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months
    • DOI 10.1097/01.TP.0000062837.99400.60
    • Gonwa T, Mendez R, Yang HC, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months. Transplantation 2003;75:1213-20 (Pubitemid 36513023)
    • (2003) Transplantation , vol.75 , Issue.8 , pp. 1213-1220
    • Gonwa, T.1    Mendez, R.2    Yang, H.C.3    Weinstein, S.4    Jensik, S.5    Steinberg, S.6
  • 119
    • 10744225688 scopus 로고    scopus 로고
    • A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (neoral)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year
    • DOI 10.1097/01.TP.0000101495.22734.07
    • Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004;77:252-8 (Pubitemid 38155755)
    • (2004) Transplantation , vol.77 , Issue.2 , pp. 252-258
    • Ciancio, G.1    Burke, G.W.2    Gaynor, J.J.3    Mattiazzi, A.4    Roth, D.5    Kupin, W.6    Nicolas, M.7    Ruiz, P.8    Rosen, A.9    Miller, J.10
  • 120
    • 0037775561 scopus 로고    scopus 로고
    • A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients
    • van Hooff JP, Squifflet JP, Wlodarczyk Z, et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 2003;75:1934-9 (Pubitemid 36793271)
    • (2003) Transplantation , vol.75 , Issue.12 , pp. 1934-1939
    • Van Hooff, J.P.1    Squifflet, J.-P.2    Wlodarczyk, Z.3    Vanrenterghem, Y.4    Paczek, L.5
  • 122
    • 79955867676 scopus 로고    scopus 로고
    • Comparable renal function at 6 months with Tacrolimus combined with fixed-dose Sirolimus or MMF: Results of a randomized multicenter trial in renal transplantation
    • 2010pii
    • Van Gurp E, Bustamante J, Franco A, et al. Comparable renal function at 6 months with Tacrolimus combined with fixed-dose Sirolimus or MMF: Results of a randomized multicenter trial in renal transplantation. J Transplant 2010;2010:pii: 731426
    • (2010) J Transplant , pp. 731426
    • Van Gurp, E.1    Bustamante, J.2    Franco, A.3
  • 123
    • 26644455270 scopus 로고    scopus 로고
    • Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy
    • DOI 10.1097/01.tp.0000173378.28790.0b
    • Anil Kumar MS, Heifets M, Fyfe B, et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005;80:807-14 (Pubitemid 41443764)
    • (2005) Transplantation , vol.80 , Issue.6 , pp. 807-814
    • Kumar, M.S.A.1    Heifets, M.2    Fyfe, B.3    Saaed, M.I.4    Moritz, M.J.5    Parikh, M.H.6    Kumar, A.7
  • 124
    • 79958706027 scopus 로고    scopus 로고
    • Steroid minimization for sirolimus-treated renal transplant recipients
    • Matas AJ, Granger D, Kaufman DB, et al. Steroid minimization for sirolimus-treated renal transplant recipients. Clin Transplant 2011;25:457-67
    • (2011) Clin Transplant , vol.25 , pp. 457-467
    • Matas, A.J.1    Granger, D.2    Kaufman, D.B.3
  • 125
    • 27644576791 scopus 로고    scopus 로고
    • Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus
    • DOI 10.1111/j.1600-6143.2005.01019.x
    • Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005;5:2273-80 (Pubitemid 41648476)
    • (2005) American Journal of Transplantation , vol.5 , Issue.9 , pp. 2273-2280
    • Meier-Kriesche, H.-U.1    Schold, J.D.2    Srinivas, T.R.3    Howard, R.J.4    Fujita, S.5    Kaplan, B.6
  • 126
    • 83655178312 scopus 로고    scopus 로고
    • A regimen of Sirolimus and reduced-dose Cyclosporine results in improved renal allograft function: Combined analysis of the U.S. and European Sirolimus-Cyclosporine trials
    • Meeting Abstract 459
    • Cohen D. A regimen of Sirolimus and reduced-dose Cyclosporine results in improved renal allograft function: Combined analysis of the U.S. AND European Sirolimus-Cyclosporine trials. Am J Transplant 2004;4(Suppl 8):284; Meeting Abstract 459
    • (2004) Am J Transplant , vol.4 , Issue.SUPPL. 8 , pp. 284
    • Cohen, D.1
  • 127
    • 57649088471 scopus 로고    scopus 로고
    • Fifteen years of clinical studies and clinical practice in renal transplantation: Reviewing outcomes with de novo use of sirolimus in combination with cyclosporine
    • Kahan BD. Fifteen years of clinical studies and clinical practice in renal transplantation: Reviewing outcomes with de novo use of sirolimus in combination with cyclosporine. Transplant Proc 2008;40:S17-20
    • (2008) Transplant Proc , vol.40
    • Kahan, B.D.1
  • 128
    • 80054737136 scopus 로고    scopus 로고
    • Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment
    • Pliszczynski J, Kahan BD. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment. Transplant Proc 2011;43:3657-68
    • (2011) Transplant Proc , vol.43 , pp. 3657-3668
    • Pliszczynski, J.1    Kahan, B.D.2
  • 129
    • 57649110384 scopus 로고    scopus 로고
    • Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: Results from an open-label, randomized trial
    • Gaber AO, Kahan BD, Van Buren C, et al. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: Results from an open-label, randomized trial. Transplantation 2008;86:1187-95
    • (2008) Transplantation , vol.86 , pp. 1187-1195
    • Gaber, A.O.1    Kahan, B.D.2    Van Buren, C.3
  • 132
    • 19244366256 scopus 로고    scopus 로고
    • Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients
    • Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002;2:436-42
    • (2002) Am J Transplant , vol.2 , pp. 436-442
    • Morales, J.M.1    Wramner, L.2    Kreis, H.3
  • 133
    • 34247582790 scopus 로고    scopus 로고
    • Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-Year results of a randomized prospective trial compared to calcineurin inhibitor drugs
    • DOI 10.1097/01.tp.0000258586.52777.4c, PII 0000789020070415000007
    • Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007;83:883-92 (Pubitemid 46682728)
    • (2007) Transplantation , vol.83 , Issue.7 , pp. 883-892
    • Flechner, S.M.1    Goldfarb, D.2    Solez, K.3    Modlin, C.S.4    Mastroianni, B.5    Savas, K.6    Babineau, D.7    Kurian, S.8    Salomon, D.9    Novick, A.C.10    Cook, D.J.11
  • 135
    • 34548593235 scopus 로고    scopus 로고
    • Calcineurin inhibitor-free immunosuppression in kidney transplantation
    • DOI 10.1111/j.1432-2277.2007.00528.x
    • Guerra G, Srinivas TR, Meier-Kriesche HU. Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transpl Int 2007;20:813-27 (Pubitemid 47390195)
    • (2007) Transplant International , vol.20 , Issue.10 , pp. 813-827
    • Guerra, G.1    Srinivas, T.R.2    Meier-Kriesche, H.-U.3
  • 136
    • 70350458840 scopus 로고    scopus 로고
    • Prospective observational study of sirolimus as primary immunosuppression after renal transplantation
    • Pescovitz MD, Nezakatgoo N, Lorber MI, et al. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. Transplantation 2009;88:1010-18
    • (2009) Transplantation , vol.88 , pp. 1010-1018
    • Pescovitz, M.D.1    Nezakatgoo, N.2    Lorber, M.I.3
  • 137
    • 2342596401 scopus 로고    scopus 로고
    • Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation
    • Lo A, Egidi MF, Gaber LW, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 2004;77:1228-35 (Pubitemid 38580302)
    • (2004) Transplantation , vol.77 , Issue.8 , pp. 1228-1235
    • Lo, A.1    Egidi, M.F.2    Gaber, L.W.3    Amiri, H.-S.4    Vera, S.5    Nezakatgoo, N.6    Gaber, A.O.7
  • 139
    • 48049104898 scopus 로고    scopus 로고
    • Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients
    • Hamdy AF, Bakr MA, Ghoneim MA. Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients. J Am Soc Nephrol 2008;19:1225-32
    • (2008) J Am Soc Nephrol , vol.19 , pp. 1225-1232
    • Hamdy, A.F.1    Bakr, M.A.2    Ghoneim, M.A.3
  • 141
    • 67650938542 scopus 로고    scopus 로고
    • Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation
    • Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation. Am J Transplant 2009;9:1876-85
    • (2009) Am J Transplant , vol.9 , pp. 1876-1885
    • Ekberg, H.1    Bernasconi, C.2    Tedesco-Silva, H.3
  • 143
    • 79961023382 scopus 로고    scopus 로고
    • The search goes on
    • The search goes on. Am J Transplant 2011;11:1551-2
    • (2011) Am J Transplant , Issue.11 , pp. 1551-1552
  • 144
    • 79961032806 scopus 로고    scopus 로고
    • The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients
    • Flechner SM, Glyda M, Cockfield S, et al. The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011;11:1633-44
    • (2011) Am J Transplant , vol.11 , pp. 1633-1644
    • Flechner, S.M.1    Glyda, M.2    Cockfield, S.3
  • 145
    • 0035884710 scopus 로고    scopus 로고
    • Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure
    • Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001;72:777-86 (Pubitemid 32879845)
    • (2001) Transplantation , vol.72 , Issue.5 , pp. 777-786
    • Johnson, R.W.G.1    Kreis, H.2    Oberbauer, R.3    Brattstrom, C.4    Claesson, K.5    Eris, J.6
  • 147
    • 77954952597 scopus 로고    scopus 로고
    • Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial
    • Guba M, Pratschke J, Hugo C, et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial. Transplantation 2010;90:175-83
    • (2010) Transplantation , vol.90 , pp. 175-183
    • Guba, M.1    Pratschke, J.2    Hugo, C.3
  • 148
    • 65249134974 scopus 로고    scopus 로고
    • Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study
    • Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009;9:1115-23
    • (2009) Am J Transplant , vol.9 , pp. 1115-1123
    • Lebranchu, Y.1    Thierry, A.2    Toupance, O.3
  • 149
    • 79953243656 scopus 로고    scopus 로고
    • Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial
    • Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial. Kidney Int 2011;79:897-907
    • (2011) Kidney Int , vol.79 , pp. 897-907
    • Weir, M.R.1    Mulgaonkar, S.2    Chan, L.3
  • 150
    • 79961039264 scopus 로고    scopus 로고
    • Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study
    • Lebranchu Y, Thierry A, Thervet E, et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011;11:1665-75
    • (2011) Am J Transplant , Issue.11 , pp. 1665-1675
    • Lebranchu, Y.1    Thierry, A.2    Thervet, E.3
  • 152
    • 84860431997 scopus 로고    scopus 로고
    • Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation
    • Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012;12:1192-8
    • (2012) Am J Transplant , vol.12 , pp. 1192-1198
    • Liefeldt, L.1    Brakemeier, S.2    Glander, P.3
  • 153
    • 84865582415 scopus 로고    scopus 로고
    • Does everolimus increase donor-specific hla antibodies in kidney transplant recipients?
    • doi: 10.1111/j.1600-6143.2012.04159.x. (Epub ahead of print
    • Pascual J, ArnsW. Does everolimus increase donor-specific HLA antibodies in kidney transplant recipients? Am J Transplant 2012; doi: 10.1111/j.1600-6143. 2012.04159.x. (Epub ahead of print)
    • (2012) Am J Transplant
    • Pascual, J.1    Arns, W.2
  • 154
    • 80053294998 scopus 로고    scopus 로고
    • Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial
    • Alberu J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011;92:303-10
    • (2011) Transplantation , Issue.92 , pp. 303-310
    • Alberu, J.1    Pascoe, M.D.2    Campistol, J.M.3
  • 155
    • 59649126728 scopus 로고    scopus 로고
    • Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial
    • Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87:233-42
    • (2009) Transplantation , vol.87 , pp. 233-242
    • Schena, F.P.1    Pascoe, M.D.2    Alberu, J.3
  • 156
    • 84858444345 scopus 로고    scopus 로고
    • Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: Observational results at 24 and 36 months after transplantation
    • Guba M, Pratschke J, Hugo C, et al. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: Observational results at 24 and 36 months after transplantation. Transpl Int 2012;25:416-23
    • (2012) Transpl Int , vol.25 , pp. 416-423
    • Guba, M.1    Pratschke, J.2    Hugo, C.3
  • 157
    • 79957815201 scopus 로고    scopus 로고
    • Sirolimus: Not so sparing in the Spare-the-Nephron trial
    • author reply -1379 author rep80
    • Shamseddin MK, Gupta A. Sirolimus: not so sparing in the Spare-the-Nephron trial. Kidney Int 2011;79:1379; author reply -80
    • (2011) Kidney Int , Issue.79 , pp. 1379
    • Shamseddin, M.K.1    Gupta, A.2
  • 158
    • 33750991068 scopus 로고    scopus 로고
    • Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence
    • DOI 10.1097/01.tp.0000237101.58974.43, PII 0000789020061115000008
    • Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 2006;82:1153-62 (Pubitemid 44748017)
    • (2006) Transplantation , vol.82 , Issue.9 , pp. 1153-1162
    • Mulay, A.V.1    Cockfield, S.2    Stryker, R.3    Fergusson, D.4    Knoll, G.A.5
  • 162
    • 53449096010 scopus 로고    scopus 로고
    • Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma
    • Barozzi P, Bonini C, Potenza L, et al. Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation 2008;86:738-44
    • (2008) Transplantation , vol.86 , pp. 738-744
    • Barozzi, P.1    Bonini, C.2    Potenza, L.3
  • 164
    • 1642371460 scopus 로고    scopus 로고
    • Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma
    • DOI 10.1097/01.TP.0000115344.18025.0B
    • Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004;77:760-2 (Pubitemid 38366986)
    • (2004) Transplantation , vol.77 , Issue.5 , pp. 760-762
    • Campistol, J.M.1    Gutierrez-Dalmau, A.2    Torregrosa, J.V.3
  • 165
    • 27644436740 scopus 로고    scopus 로고
    • Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies
    • DOI 10.1097/01.TP.0000184006.43152.8D
    • Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-9 (Pubitemid 41552882)
    • (2005) Transplantation , vol.80 , Issue.7 , pp. 883-889
    • Kauffman, H.M.1    Cherikh, W.S.2    Cheng, Y.3    Hanto, D.W.4    Kahan, B.D.5
  • 166
    • 65549140711 scopus 로고    scopus 로고
    • Minimizing the risk of posttransplant malignancy
    • Campistol JM. Minimizing the risk of posttransplant malignancy. Transplantation 2009;87:S19-22
    • (2009) Transplantation , vol.87
    • Campistol, J.M.1
  • 167
    • 77952940222 scopus 로고    scopus 로고
    • Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: Reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial
    • Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: Reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010;10:1385-93
    • (2010) Am J Transplant , vol.10 , pp. 1385-1393
    • Salgo, R.1    Gossmann, J.2    Schofer, H.3
  • 168
    • 84860471709 scopus 로고    scopus 로고
    • Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer
    • Campbell SB, Walker R, Tai SS, et al. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012;12:1146-56
    • (2012) Am J Transplant , vol.12 , pp. 1146-1156
    • Campbell, S.B.1    Walker, R.2    Tai, S.S.3
  • 169
    • 84874191837 scopus 로고    scopus 로고
    • Reduced rate of cutaneous squamous cell carcinoma in a randomised, prospective, multi-centre controlled trial of conversion to sirolimus-based immunosuppression: The rescue Trial
    • Harden PN, vdA JMH, Bouwes-Bavinck JN, et al. Reduced rate of cutaneous squamous cell carcinoma in a randomised, prospective, multi-centre controlled trial of conversion to sirolimus-based immunosuppression: The RESCUE Trial. Transplant International 2011;24(Suppl s2):94-5
    • (2011) Transplant International , vol.24 , Issue.SUPPL. 2 , pp. 94-95
    • Harden, P.N.1    Vda, J.M.H.2    Bouwes-Bavinck, J.N.3
  • 170
    • 0042833239 scopus 로고    scopus 로고
    • De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: Role of sirolimus
    • DOI 10.1016/S0041-1345(03)00614-6
    • Franco A, Hernandez D, Capdevilla L, et al. De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: Role of sirolimus. Transplant Proc 2003;35:1764-6 (Pubitemid 37093703)
    • (2003) Transplantation Proceedings , vol.35 , Issue.5 , pp. 1764-1766
    • Franco, A.1    Hernandez, D.2    Capdevilla, L.3    Errasti, P.4    Gonzalez, M.5    Ruiz, J.C.6    Sanchez, J.7
  • 171
    • 77952558567 scopus 로고    scopus 로고
    • A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: Case report
    • Albertazzi V, Bonucchi D, De Amicis S, et al. A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: Case report. Transplant Proc 2010;42:1352-4
    • (2010) Transplant Proc , Issue.42 , pp. 1352-1354
    • Albertazzi, V.1    Bonucchi, D.2    De Amicis, S.3
  • 173
    • 78349306789 scopus 로고    scopus 로고
    • Sirolimus for calcineurin inhibitors in organ transplantation: Contra
    • Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus for calcineurin inhibitors in organ transplantation: Contra. Kidney Int 2010;78:1068-74
    • (2010) Kidney Int , vol.78 , pp. 1068-1074
    • Cravedi, P.1    Ruggenenti, P.2    Remuzzi, G.3
  • 174
    • 14644403072 scopus 로고    scopus 로고
    • Benefit-risk assessment of sirolimus in renal transplantation
    • DOI 10.2165/00002018-200528020-00006
    • Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005;28:153-81 (Pubitemid 40321770)
    • (2005) Drug Safety , vol.28 , Issue.2 , pp. 153-181
    • Kuypers, D.R.J.1
  • 175
    • 33947193386 scopus 로고    scopus 로고
    • Use of sirolimus in solid organ transplantation
    • DOI 10.2165/00003495-200767030-00004
    • Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007;67:369-91 (Pubitemid 46425551)
    • (2007) Drugs , vol.67 , Issue.3 , pp. 369-391
    • Augustine, J.J.1    Bodziak, K.A.2    Hricik, D.E.3
  • 176
    • 84856850359 scopus 로고    scopus 로고
    • Mtor inhibition and erythropoiesis: Microcytosis or anaemia?
    • Diekmann F, Rovira J, Diaz-Ricart M, et al. mTOR inhibition and erythropoiesis: Microcytosis or anaemia? Nephrol Dial Transplant 2012;27:537-41
    • (2012) Nephrol Dial Transplant , Issue.27 , pp. 537-541
    • Diekmann, F.1    Rovira, J.2    Diaz-Ricart, M.3
  • 178
    • 82655189405 scopus 로고    scopus 로고
    • Conversion from a calcineurin inhibitor to a sirolimus-based therapy after renal transplantation - An update of existing recommendations
    • Arns W, Budde K, Eitner F, et al. Conversion from a calcineurin inhibitor to a sirolimus-based therapy after renal transplantation - An update of existing recommendations. Dtsch Med Wochenschr 2011;136:2554-9
    • (2011) Dtsch Med Wochenschr , vol.136 , pp. 2554-2559
    • Arns, W.1    Budde, K.2    Eitner, F.3
  • 179
  • 181
    • 66949118919 scopus 로고    scopus 로고
    • Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation
    • Campistol JM, Cockwell P, Diekmann F, et al. Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int 2009;22:681-7
    • (2009) Transpl Int , vol.22 , pp. 681-687
    • Campistol, J.M.1    Cockwell, P.2    Diekmann, F.3
  • 182
    • 0034649707 scopus 로고    scopus 로고
    • Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients
    • Singer SJ, Tiernan R, Sullivan EJ. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000;343:1815-16
    • (2000) N Engl J Med , vol.343 , pp. 1815-1816
    • Singer, S.J.1    Tiernan, R.2    Sullivan, E.J.3
  • 184
    • 84155180920 scopus 로고    scopus 로고
    • Pneumocystis jirovecii pneumonia in kidney transplantation
    • Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis 2011;13:551-8
    • (2011) Transpl Infect Dis , vol.13 , pp. 551-558
    • Goto, N.1    Oka, S.2
  • 187
    • 33847235398 scopus 로고    scopus 로고
    • Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: An overview
    • Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: An overview. Transpl Int 2007;20:305-11
    • (2007) Transpl Int , vol.20 , pp. 305-311
    • Huyghe, E.1    Zairi, A.2    Nohra, J.3
  • 188
    • 84860743864 scopus 로고    scopus 로고
    • Sirolimus-associated testicular toxicity: Detrimental but reversible
    • Rovira J, Diekmann F, Ramirez-Bajo MJ, et al. Sirolimus-associated testicular toxicity: Detrimental but reversible. Transplantation 2012;93:874-9
    • (2012) Transplantation , vol.93 , pp. 874-879
    • Rovira, J.1    Diekmann, F.2    Ramirez-Bajo, M.J.3
  • 189
    • 84858257135 scopus 로고    scopus 로고
    • Ovarian toxicity from sirolimus
    • Braun M, Young J, Reiner CS, et al. Ovarian toxicity from sirolimus. N Engl J Med 2012;366:1062-4
    • (2012) N Engl J Med , vol.366 , pp. 1062-1064
    • Braun, M.1    Young, J.2    Reiner, C.S.3
  • 190
    • 78649261874 scopus 로고    scopus 로고
    • Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk
    • Liefeldt L, Budde K. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl Int 2010;23:1191-204
    • (2010) Transpl Int , vol.23 , pp. 1191-1204
    • Liefeldt, L.1    Budde, K.2
  • 191
    • 42449104351 scopus 로고    scopus 로고
    • Mtor inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes
    • Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008;57:945-57
    • (2008) Diabetes , vol.57 , pp. 945-957
    • Fraenkel, M.1    Ketzinel-Gilad, M.2    Ariav, Y.3
  • 192
    • 38149083478 scopus 로고    scopus 로고
    • Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway
    • Kim JH, Kim JE, Liu HY, et al. Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol Chem 2008;283:708-15
    • (2008) J Biol Chem , vol.283 , pp. 708-715
    • Kim, J.H.1    Kim, J.E.2    Liu, H.Y.3
  • 193
    • 32844474879 scopus 로고    scopus 로고
    • Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus
    • DOI 10.1681/ASN.2005050487
    • Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16:3128-35 (Pubitemid 44743511)
    • (2005) Journal of the American Society of Nephrology , vol.16 , Issue.10 , pp. 3128-3135
    • Teutonico, A.1    Schena, P.F.2    Di Paolo, S.3
  • 194
    • 48149112155 scopus 로고    scopus 로고
    • Sirolimus is associated with new-onset diabetes in kidney transplant recipients
    • Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411-18
    • (2008) J Am Soc Nephrol , vol.19 , pp. 1411-1418
    • Johnston, O.1    Rose, C.L.2    Webster, A.C.3    Gill, J.S.4
  • 196
    • 67949084959 scopus 로고    scopus 로고
    • Mammalian target of rapamycin and diabetes: What does the current evidence tell us?
    • Vodenik B, Rovira J, Campistol JM. Mammalian target of rapamycin and diabetes: What does the current evidence tell us? Transplant Proc 2009;41:S31-8
    • (2009) Transplant Proc , vol.41
    • Vodenik, B.1    Rovira, J.2    Campistol, J.M.3
  • 197
    • 83655178312 scopus 로고    scopus 로고
    • A regimen of sirolimus and reduced-dose cyclosporine results in improved renal allograft function: Combined analysis of the U.S. and European sirolimus-cyclosporine trials
    • Cohen D. A regimen of sirolimus and reduced-dose cyclosporine results in improved renal allograft function: Combined analysis of the U.S. and European sirolimus-cyclosporine trials. Am J Transplant 2004;5(12):p. 2937-44
    • (2004) Am J Transplant , vol.5 , Issue.12 , pp. 2937-2944
    • Cohen, D.1
  • 198
    • 10744220677 scopus 로고    scopus 로고
    • A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year
    • DOI 10.1097/01.TP.0000101290.20629.DC
    • Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004;77:244-51 (Pubitemid 38155754)
    • (2004) Transplantation , vol.77 , Issue.2 , pp. 244-251
    • Ciancio, G.1    Burke, G.W.2    Gaynor, J.J.3    Mattiazzi, A.4    Roth, D.5    Kupin, W.6    Nicolas, M.7    Ruiz, P.8    Rosen, A.9    Miller, J.10
  • 199
    • 14544295706 scopus 로고    scopus 로고
    • Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus
    • Kamar N, Allard J, Ribes D, et al. Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus. Clin Nephrol 2005;63:80-6 (Pubitemid 40298041)
    • (2005) Clinical Nephrology , vol.63 , Issue.2 , pp. 80-86
    • Kamar, N.1    Allard, J.2    Ribes, D.3    Durand, D.4    Ader, J.L.5    Rostaing, L.6
  • 201
    • 74549126028 scopus 로고    scopus 로고
    • Why do patients develop proteinuria with sirolimus? Do we have the answer?
    • Chapman JR, Rangan GK. Why do patients develop proteinuria with sirolimus? Do we have the answer? Am J Kidney Dis 2010;55:213-16
    • (2010) Am J Kidney Dis , vol.55 , pp. 213-216
    • Chapman, J.R.1    Rangan, G.K.2
  • 204
    • 68949212921 scopus 로고    scopus 로고
    • Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction
    • Gutierrez MJ, Gonzalez E, Andres A, Morales JM. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction. Transplant Proc 2009;41:2348-50
    • (2009) Transplant Proc , vol.41 , pp. 2348-2350
    • Gutierrez, M.J.1    Gonzalez, E.2    Andres, A.3    Morales, J.M.4
  • 205
    • 40649124774 scopus 로고    scopus 로고
    • MToR inhibitors-induced proteinuria: Mechanisms, significance, and management
    • DOI 10.1016/j.trre.2007.12.001, PII S0955470X07001280
    • Letavernier E. Legendre C. mToR inhibitors-induced proteinuria: Mechanisms, significance, and management. Transplant Rev (Orlando) 2008;22:125-30 (Pubitemid 351372914)
    • (2008) Transplantation Reviews , vol.22 , Issue.2 , pp. 125-130
    • Letavernier, E.1    Legendre, C.2
  • 206
    • 33644536111 scopus 로고    scopus 로고
    • Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients
    • Boratynska M, Banasik M, Watorek E, et al. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006;38:101-4
    • (2006) Transplant Proc , vol.38 , pp. 101-104
    • Boratynska, M.1    Banasik, M.2    Watorek, E.3
  • 207
    • 54149120306 scopus 로고    scopus 로고
    • Conversion to sirolimus for chronic renal allograft dysfunction: Risk factors for graft loss and severe side effects
    • Abramowicz D, Hadaya K, Hazzan M, et al. Conversion to sirolimus for chronic renal allograft dysfunction: Risk factors for graft loss and severe side effects. Nephrol Dial Transplant 2008;23:3727-9
    • (2008) Nephrol Dial Transplant , vol.23 , pp. 3727-3729
    • Abramowicz, D.1    Hadaya, K.2    Hazzan, M.3
  • 208
    • 38049110352 scopus 로고    scopus 로고
    • Conversion to sirolimus for chronic allograft dysfunction: Long-term results confirm predictive value of proteinuria
    • Diekmann F, Budde K, Slowinski T, et al. Conversion to sirolimus for chronic allograft dysfunction: Long-term results confirm predictive value of proteinuria. Transpl Int 2008;21:152-5
    • (2008) Transpl Int , vol.21 , pp. 152-155
    • Diekmann, F.1    Budde, K.2    Slowinski, T.3
  • 209
    • 68249101040 scopus 로고    scopus 로고
    • Posttransplant anemia: The role of sirolimus
    • Fishbane S, Cohen DJ, Coyne DW, et al. Posttransplant anemia: The role of sirolimus. Kidney Int 2009;76:376-82
    • (2009) Kidney Int , vol.76 , pp. 376-382
    • Fishbane, S.1    Cohen, D.J.2    Coyne, D.W.3
  • 210
    • 67651115805 scopus 로고    scopus 로고
    • The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: The Symphony pharmacokinetic substudy
    • Grinyo JM, Ekberg H, Mamelok RD, et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: The Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009;24:2269-76
    • (2009) Nephrol Dial Transplant , vol.24 , pp. 2269-2276
    • Grinyo, J.M.1    Ekberg, H.2    Mamelok, R.D.3
  • 211
    • 77749325097 scopus 로고    scopus 로고
    • Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation
    • Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010;5:341-58
    • (2010) Clin J Am Soc Nephrol , Issue.5 , pp. 341-358
    • Kuypers, D.R.1    Le Meur, Y.2    Cantarovich, M.3
  • 212
    • 79953718025 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of mycophenolates in kidney transplantation: Report of the Transplantation Society consensus meeting
    • Le Meur Y, Borrows R, Pescovitz MD, et al. Therapeutic drug monitoring of mycophenolates in kidney transplantation: Report of The Transplantation Society consensus meeting. Transplant Rev (Orlando) 2011;25:58-64
    • (2011) Transplant Rev (Orlando , vol.25 , pp. 58-64
    • Le Meur, Y.1    Borrows, R.2    Pescovitz, M.D.3
  • 213
    • 77950933411 scopus 로고    scopus 로고
    • Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients
    • Duerr M, Glander P, Diekmann F, et al. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010;5:703-8
    • (2010) Clin J Am Soc Nephrol , Issue.5 , pp. 703-708
    • Duerr, M.1    Glander, P.2    Diekmann, F.3
  • 215
    • 64049111999 scopus 로고    scopus 로고
    • Sirolimus to replace calcineurin inhibitors? Too early yet
    • Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus to replace calcineurin inhibitors? Too early yet. Lancet 2009;373:1235-6
    • (2009) Lancet , vol.373 , pp. 1235-1236
    • Cravedi, P.1    Ruggenenti, P.2    Remuzzi, G.3
  • 216
    • 80053313905 scopus 로고    scopus 로고
    • Switching from calcineurin inhibitors to Mammalian target of rapamycin inhibitors-finally caught the right wave?
    • Naesens M. Switching from calcineurin inhibitors to Mammalian target of rapamycin inhibitors-finally caught the right wave? Transplantation 2011;92:728-30
    • (2011) Transplantation , vol.92 , pp. 728-730
    • Naesens, M.1
  • 217
    • 84864245430 scopus 로고    scopus 로고
    • Sirolimus and secondary skin-cancer prevention in kidney transplantation
    • Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012;367:329-39
    • (2012) N Engl J Med , Issue.367 , pp. 329-339
    • Euvrard, S.1    Morelon, E.2    Rostaing, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.